Clinical Trials Logo

Cluster Headache clinical trials

View clinical trials related to Cluster Headache.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04570475 Terminated - Cluster Headache Clinical Trials

High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache

Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

This study intends to investigate the use of high-dose Vitamin D3 plus a multivitamin in the prevention of cluster headache attacks. Participants can be enrolled anywhere in the United States that has access to one of our participating labs (for blood work - anticipated to be available in most of the USA). The study may include: - Screening: Participants may be interviewed, examined, fill out surveys, and get blood testing - Week 1: baseline period (no added medications - to establish a baseline) - Weeks 2-4: double-blinded experimental period - participants receive either 1) high-dose Vitamin D3 + multivitamin, or 2) placebo + multivitamin. Participants also fill out a survey and have blood testing. - Weeks 5-7: open-label period - ALL participants receive high-dose Vitamin D3 + multivitamin. Participants also fill out a survey and may have blood testing. Specifically, our primary outcome is the change from baseline to experimental weeks 1-3 in the frequency of cluster headache attacks between placebo and high-dose vitamin D. Specific primary and secondary outcomes are listed below.

NCT ID: NCT04439409 Terminated - Cluster Headache Clinical Trials

Variability of the Autonomic Nervous System (ANS) During Cluster Headache (CH).

AVASNA
Start date: August 19, 2020
Phase:
Study type: Observational

Cluster Headache (CH) is associated with ipsilateral vegetative signs, related to parasympathetic system hyperactivity and/or signs of sympathetic hypoactivity. The precise mechanism of Cluster Headache (CH) is still unknown. The question is whether these dysautonomic disorders are simply secondary to the Cluster Headache (CH) process or whether they are the triggering factor.

NCT ID: NCT04280055 Terminated - Cluster Headache Clinical Trials

Prophylactic Effects of Psilocybin on Chronic Cluster Headache

EPOCH
Start date: January 21, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the prophylactic effects of psilocybin in chronic cluster headache. Subjects will receive a low dose of psilocybin during 3 sessions spaced by one week. Subjects will maintain a headache diary prior to, during, and after the administrations in order to document headache frequency, intensity and duration. Subjects will undergo a fMRI scanning before the first and after the last psilocybin session.

NCT ID: NCT03107052 Terminated - Cluster Headache Clinical Trials

A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache

ENFORCE
Start date: April 27, 2017
Phase: Phase 3
Study type: Interventional

This is a 68-week study to evaluate the long-term safety and efficacy of fremanezumab in participants with cluster headache (CH). Participants who complete the pivotal studies TV48125-CNS-30056 (NCT02945046) and TV48125-CNS-30057 (NCT02964338) and enroll into the current study will visit the investigational center for investigational medicinal product (IMP) administration, safety and efficacy assessments, and blood and urine collections for pharmacokinetics, immunogenicity (anti-drug antibodies [ADAs]), and biomarker analyses. Participants will return to the investigational center for a follow-up visit to evaluate ADAs, fremanezumab concentrations, biomarkers, and safety (adverse events and concomitant medications) approximately 7.5 months after the last dose of IMP.

NCT ID: NCT02964338 Terminated - Clinical trials for Chronic Cluster Headache

A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)

Start date: January 17, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the current study is to evaluate the efficacy and safety of Fremanezumab (TEV-48125), in the prevention of CCH in adult participants.

NCT ID: NCT02945046 Terminated - Clinical trials for Episodic Cluster Headache

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

Start date: January 19, 2017
Phase: Phase 3
Study type: Interventional

This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 (Fremanezumab) versus placebo in adult participants for the prevention of ECH.

NCT ID: NCT02619617 Terminated - Clinical trials for Cluster Headache - Episodic and Chronic

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

Start date: October 31, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.

NCT ID: NCT02381795 Terminated - Cluster Headache Clinical Trials

Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache

Start date: July 2015
Phase: Phase 2
Study type: Interventional

This is an open label, investigator-sponsored, pilot study. Subjects agreeing to participate in the study and meeting the eligibility criteria assessed at the screening visit will be enrolled in the study. The length of time between screening and treatment will last between 0 days to a maximum of 12 weeks. Subjects who enter the screening phase during a cluster headache episode and meet the study eligibility criteria can immediately enter the treatment phase and may opt to treat their cluster headache episode in the clinic. Subjects who are not in a cluster headache episode, who meet initial screening eligibility criteria, can remain in the screening phase for up to 12 weeks until their next cluster episode begins. Upon initiation of a cluster headache episode, subjects will enter the treatment period. Subjects will be trained on the proper use of the hand-held dispenser containing carbon dioxide (CO2 )calibrated to deliver 0.5 standard liters per minute (SLPM). This dispenser will be provided for use in the clinic or home. Subjects will be instructed to use the nasal CO2 dispenser, 10 seconds/nostril, as needed up to 6 times to treat one attack. Each dose must be separated by 3-5 minutes. Subjects should treat only one attack in a 24-hour period. Subjects may treat up to three cluster headache attacks during the treatment phase of this study. One hour after the first dose, subjects can choose to treat with investigator-approved rescue medication. Subjects will be asked to complete an online diary after the completion of the dosing. Diary assessments will collect pain severity, nasal CO2 usage, acute medication usage, satisfaction of treatment, number of cluster attacks, and unusual symptoms. Subjects will be contacted by phone within 3 days of the first use of the nasal CO2 dispenser to assess adverse events (AEs) and medication usage. A total of 25 subjects will enter the treatment period and be instructed to treat up to 3 cluster headaches with nasal CO2. Within 7 days of treating their last cluster headache episode, subjects will return for an end of study visit.

NCT ID: NCT02209155 Terminated - Clinical trials for Episodic Cluster Headache

R-Verapamil for the Prophylaxis of Episodic Cluster Headache

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This is a double-blinded, randomized, parallel, placebo-controlled phase 2 study to evaluate the safety and efficacy of R-verapamil in the prophylaxis of episodic cluster headache.

NCT ID: NCT01406860 Terminated - Clinical trials for Primary Headaches (Includes Migraines, Tension, Cluster Headaches)

Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches

Start date: July 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if droperidol is equally as effective as metoclopramide for treatment of primary headaches in the Emergency Department.